



# Sesquiterpenes from *Streptomyces qinglanensis* and Their Cytotoxic Activity

<b>Figure S1.</b> <sup>1</sup> H NMR spectrum of <b>1</b> .....	3
<b>Figure S2.</b> <sup>13</sup> C NMR spectrum of <b>1</b> .....	4
<b>Figure S3.</b> HSQC spectrum of <b>1</b> . ....	5
<b>Figure S4.</b> <sup>1</sup> H- <sup>1</sup> H COSY spectrum of <b>1</b> .....	6
<b>Figure S5.</b> HMBC spectrum of <b>1</b> . ....	7
<b>Figure S6.</b> NOESY spectrum of <b>1</b> .....	8
<b>Figure S7.</b> HRESI MS data of <b>1</b> .....	9
<b>Figure S8.</b> Comparison of chemical shifts of <b>4</b> and <b>6</b> . ....	10
<b>Figure S9.</b> <sup>1</sup> H NMR spectrum of <b>4</b> .....	11
<b>Figure S10.</b> <sup>13</sup> C NMR spectrum of <b>4</b> .....	12
<b>Figure S11.</b> HSQC spectrum of <b>4</b> . ....	13
<b>Figure S12.</b> <sup>1</sup> H- <sup>1</sup> H COSY spectrum of <b>4</b> .....	14
<b>Figure S13.</b> HMBC spectrum of <b>4</b> . ....	15
<b>Figure S14.</b> 1D selective NOESY spectrum of <b>4</b> (irradiated at H-8). ....	16
<b>Figure S15.</b> 1D selective NOESY spectrum of <b>4</b> (irradiated at H-5). ....	17
<b>Figure S16.</b> HRESIMS data of <b>4</b> .....	18
<b>Figure S17.</b> <sup>1</sup> H NMR spectrum of <b>7</b> .....	19
<b>Figure S18.</b> <sup>13</sup> C NMR spectrum of <b>7</b> .....	20
<b>Figure S19.</b> HSQC spectrum of <b>7</b> . ....	21
<b>Figure S 20.</b> <sup>1</sup> H- <sup>1</sup> H COSY spectrum of <b>7</b> .....	22
<b>Figure S21.</b> HMBC spectrum of <b>7</b> . ....	23
<b>Figure S22.</b> NOESY spectrum of <b>7</b> .....	24
<b>Figure S23.</b> 1D selective NOESY spectrum of <b>7</b> (irradiated at H-5). ....	25
<b>Figure S24.</b> HRESIMS data of <b>7</b> .....	26
<b>Figure S25.</b> Comparison NMR data of bolinane A ( <b>9</b> ) with bolinaquinone. ....	27
<b>Figure S26.</b> <sup>1</sup> H NMR spectrum of <b>9</b> .....	28


<b>Figure S27.</b> $^{13}\text{C}$ NMR spectrum of <b>9</b> .....	29
<b>Figure S28.</b> HSQC spectrum of <b>9</b> . ....	30
<b>Figure S29.</b> $^1\text{H}$ - $^1\text{H}$ COSY spectrum of <b>9</b> .....	31
<b>Figure S30.</b> HMBC spectrum of <b>9</b> . ....	32
<b>Figure S31.</b> Selective 1D NOESY spectrum of <b>9</b> (irradiated at $\text{H}_3$ -12). ....	33
<b>Figure S32.</b> Selective 1D NOESY spectrum of <b>9</b> (irradiated at $\text{H}_3$ -14). ....	34
<b>Figure S33.</b> Selective 1D NOESY spectrum of <b>9</b> (irradiated at $\text{H}_3$ -13). ....	35
<b>Figure S34.</b> HRESIMS data of <b>9</b> .....	36
<b>Figure S35.</b> Results of the cytotoxicity test of <b>1-9</b> against six solid cancer cell lines. ....	39
<b>Figure S36.</b> Results of the cytotoxicity test of <b>1-9</b> against seven blood cancer cell lines.....	43




**Figure S1.** <sup>1</sup>H NMR spectrum of **1**.




**Figure S2.**  $^{13}\text{C}$  NMR spectrum of **1**.




**Figure S3.** HSQC spectrum of **1**.



**Figure S4.**  $^1\text{H}$ - $^1\text{H}$  COSY spectrum of **1**.



**Figure S5.** HMBC spectrum of **1**.




**Figure S6.** NOESY spectrum of **1**.




20210720\_02\_A21-20\_KOST\_HRP\_1.21 (0.433) AM2 (Ar, 30000.0, 0.00, 0.00); ABS


1: TOF MS ES+  
1.30e6



**Figure S7.** HRESI MS data of **1**.




**4**




AA-57 methyl ester (**6**)

*J Antibiot* (Tokyo). **1978** Jul; 31 (7) : 729-31.  
doi: 10.7164/antibiotics.31.729.


**Figure S8.** Comparison of chemical shifts of **4** and **6**.




**Figure S9.**  $^1\text{H}$  NMR spectrum of **4**.




**Figure S10.** <sup>13</sup>C NMR spectrum of **4**.




**Figure S11.** HSQC spectrum of **4**.



**Figure S12.**  $^1\text{H}$ - $^1\text{H}$  COSY spectrum of **4**.




**Figure S13.** HMBC spectrum of **4**.




**Figure S14.** 1D selective NOESY spectrum of **4** (irradiated at H-8).







**Figure S15.** 1D selective NOESY spectrum of **4** (irradiated at H-5).




**Figure S16.** HRESIMS data of **4**.




**Figure S17.**  $^1\text{H}$  NMR spectrum of **7**.




**Figure S18.**  $^{13}\text{C}$  NMR spectrum of **7**.




**Figure S19.** HSQC spectrum of **7**.



**Figure S 20.**  $^1\text{H}$ - $^1\text{H}$  COSY spectrum of **7**.




**Figure S21.** HMBC spectrum of **7**.




**Figure S22.** NOESY spectrum of **7**.







**Figure S23.** 1D selective NOESY spectrum of **7** (irradiated at H-5).




**Figure S24.** HRESIMS data of **7**.




*J. Org. Chem.* **1998**, 63, 8042-8044,  
10.1021/jo981037t


**Figure S25.** Comparison NMR data of bolinane A (**9**) with bolinaquinone.




**Figure S26.** <sup>1</sup>H NMR spectrum of **9**.




**Figure S27.**  $^{13}\text{C}$  NMR spectrum of **9**.



**Figure S28.** HSQC spectrum of **9**.




**Figure S29.**  $^1\text{H}$ - $^1\text{H}$  COSY spectrum of **9**.





**Figure S30.** HMBC spectrum of **9**.






**Figure S31.** Selective 1D NOESY spectrum of **9** (irradiated at H<sub>3</sub>-12).





**Figure S33.** Selective 1D NOESY spectrum of **9** (irradiated at H<sub>3</sub>-13).



**Figure S34.** HRESIMS data of **9**.

ACHN											
Conc.(uM)	1		2		3		4		5		
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	
30	80.52	6.02	86.30	4.34	75.45	5.45	-15.53	3.40	-9.47	7.91	
10	88.42	5.74	90.30	7.11	84.29	3.31	27.38	6.75	21.55	5.26	
3	90.11	5.84	94.05	3.29	92.49	6.33	32.37	7.47	28.72	9.93	
1	89.92	2.70	97.44	1.06	95.10	5.56	87.50	4.89	84.26	5.07	
0.3	94.85	5.54	98.75	1.74	97.70	2.30	95.35	2.98	96.94	3.86	
GI50	>30		>30		>30		2.440	0.268	2.147	0.165	
Conc.(uM)	6		7		8		9		Adriamycin		
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	
30	-15.49	5.66	80.20	9.95	-14.66	2.09	76.28	7.21	3	-11.31	3.07
10	17.68	8.87	82.40	2.17	18.21	3.29	81.43	5.77	1	-6.82	8.81
3	40.66	4.80	88.08	6.96	25.64	7.09	84.05	4.43	0.3	13.78	6.87
1	76.40	8.49	95.05	5.64	82.71	5.44	95.54	3.76	0.1	44.22	6.42
0.3	92.41	3.53	96.49	4.19	96.99	3.01	97.60	5.20	0.03	97.10	4.53
GI50	2.309	0.060	>30		1.971	0.134	>30		0.095	0.005	
MDA-MB-231											
Conc.(uM)	1		2		3		4		5		
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	
30	81.19	8.29	72.09	7.13	73.48	6.08	-12.50	4.57	-10.30	7.38	
10	83.22	4.89	81.17	6.70	79.99	4.17	24.82	5.92	25.47	5.81	
3	86.02	2.26	83.20	5.66	81.53	4.97	48.39	8.77	39.53	9.02	
1	89.60	8.00	93.46	3.62	94.81	4.24	87.62	6.87	93.23	4.32	
0.3	97.66	3.67	97.26	2.52	99.27	2.67	99.41	4.94	96.27	4.18	
GI50	>30		>30		>30		3.216	0.151	2.881	0.392	
Conc.(uM)	6		7		8		9		Adriamycin		
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	
30	-10.50	7.67	77.49	4.20	-7.43	5.87	79.12	6.46	3	-12.39	3.45
10	27.33	5.27	79.99	5.58	25.97	8.37	81.53	6.44	1	-8.27	4.44
3	35.14	9.69	83.77	2.36	37.23	8.00	86.30	5.87	0.3	12.23	2.87
1	88.92	6.57	95.10	5.67	88.29	3.60	92.97	6.17	0.1	30.05	6.53
0.3	96.99	4.91	99.27	6.20	97.11	3.87	94.07	3.42	0.03	91.30	6.07
GI50	2.634	0.153	>30		2.712	0.101	>30		0.073	0.009	

**HCT-15**

Conc.(uM)	1		2		3		4		5	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
30	75.22	5.13	78.99	2.23	78.41	2.59	-9.93	2.66	-14.13	5.87
10	79.63	6.81	83.45	4.03	82.41	7.90	22.07	7.66	21.64	3.61
3	85.37	5.69	85.04	2.84	89.77	2.08	46.36	2.88	35.99	4.76
1	91.41	3.60	93.16	7.06	91.90	3.87	91.65	5.11	86.34	3.05
0.3	94.66	3.07	95.56	1.44	93.45	4.22	95.34	3.59	92.74	4.53
GI50	>30		>30		>30		3.115	0.017	2.458	0.349

	6		7		8		9			Adriamycin	
Conc.(uM)	Mean	SD	Mean	SD	Mean	SD	Mean	SD		Mean	SD
30	-4.90	4.06	81.42	3.53	-13.19	7.77	70.39	2.95	3	-13.69	3.13
10	25.15	6.52	85.08	1.29	28.71	3.67	73.27	3.77	1	-5.25	4.38
3	29.70	5.22	87.83	3.41	47.25	7.44	78.95	3.74	0.3	13.77	5.34
1	88.47	4.33	91.85	2.63	87.29	4.99	90.15	7.52	0.1	34.67	4.26
0.3	93.84	3.97	98.98	2.73	94.25	3.96	95.51	2.51	0.03	94.62	7.61
GI50	2.346	0.106	>30		3.233	0.122	>30			0.080	0.007

**PC-3**

Conc.(uM)	1		2		3		4		5	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
30	84.93	3.15	72.30	5.51	82.88	1.55	-12.50	5.51	-7.53	8.94
10	87.14	4.46	78.41	2.61	84.31	3.75	23.38	5.68	24.11	4.35
3	88.60	5.71	87.30	3.00	89.37	3.72	40.99	3.59	52.64	2.76
1	94.72	2.10	93.38	4.97	94.25	4.25	93.38	1.74	87.00	4.84
0.3	99.45	1.21	96.67	3.49	99.19	3.03	96.28	1.08	96.87	4.22
GI50	>30		>30		>30		2.881	0.059	3.456	0.028

Conc.(uM)	6		7		8		9		Adriamycin		
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	
30	-5.34	4.17	80.62	7.20	-5.68	7.86	81.49	4.94	3	-11.65	4.66
10	20.57	6.68	85.78	5.48	24.60	3.92	82.34	7.30	1	-6.62	7.00
3	43.24	5.02	87.91	6.76	45.51	5.62	89.68	2.86	0.3	17.99	7.19
1	90.56	3.71	93.53	5.05	93.51	2.55	93.11	4.82	0.1	35.47	4.32
0.3	97.58	3.53	99.79	1.99	98.86	3.21	99.34	2.97	0.03	96.53	5.36
GI50	2.922	0.197	>30		3.236	0.582	>30			0.084	0.010

NUGC-3										
Conc.(uM)	1		2		3		4		5	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
30	77.48	6.44	76.40	2.31	78.43	8.75	-20.18	3.09	-12.07	5.27
10	87.27	6.11	80.23	7.66	82.62	6.42	11.36	7.08	14.67	7.66
3	89.23	6.61	87.05	2.36	91.68	6.55	31.07	4.88	31.60	6.31
1	90.78	2.03	91.02	4.65	96.18	2.97	89.63	2.92	95.52	9.72
0.3	95.57	2.20	94.27	5.31	99.28	7.63	96.09	2.58	98.86	4.19
GI50	>30		>30		>30		2.234	0.135	2.368	0.383
Conc.(uM)	6		7		8		9		Adriamycin	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
30	-8.42	2.55	82.57	4.81	-18.34	7.00	70.81	5.07	3-15.59	7.40
10	13.07	7.03	85.95	4.77	15.04	8.53	72.09	3.98	1-2.55	4.67
3	35.22	4.33	88.30	4.96	25.34	7.95	82.43	5.71	0.3-28.07	7.70
1	91.03	4.65	92.07	5.70	84.31	8.88	86.34	3.74	0.1-35.49	5.15
0.3	96.40	4.95	96.76	2.18	93.01	5.49	93.12	7.63	0.03-97.02	6.10
GI50	2.409	0.089	>30		1.967	0.440	>30		0.092	0.023
NCI-H23										
Conc.(uM)	1		2		3		4		5	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
30	76.80	4.89	73.14	4.54	73.85	0.96	-14.64	9.83	-8.90	6.07
10	81.76	7.02	79.10	5.11	76.12	8.47	28.14	7.29	16.77	8.70
3	85.83	2.86	86.06	3.19	80.37	2.28	36.22	8.83	43.09	9.58
1	89.55	3.71	92.21	6.06	88.42	4.70	86.38	5.09	87.61	8.02
0.3	97.25	4.84	93.73	2.38	93.40	2.32	92.56	6.87	93.49	4.00
GI50	>30		>30		>30		2.604	0.017	2.734	0.349
Conc.(uM)	6		7		8		9		Adriamycin	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
30	-9.09	8.98	76.29	9.64	-16.11	3.14	80.30	2.67	3-12.52	5.33
10	19.19	5.88	79.37	5.42	26.41	6.72	84.03	6.10	1-9.96	4.52
3	41.82	5.56	83.43	5.24	31.14	8.27	86.21	7.76	0.3-17.71	6.52
1	88.79	7.43	89.94	9.52	90.31	3.09	87.18	5.35	0.1-25.15	8.75
0.3	94.67	2.52	93.73	7.45	95.45	1.71	98.14	1.61	0.03-93.70	4.84
GI50	2.753	0.106	>30		2.401	0.122	>30		0.070	0.007

**Figure S35.** Results of the cytotoxicity test of **1-9** against six solid cancer cell lines.

<b>1</b>	HL-60		Raji		K562		RPMI-8402		NALM6		U266		WSU-DLCL2	
( $\mu$ M)	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD
30	91.3	2.7	90.7	3.3	64.4	2.1	69.5	3.6	76.6	3.9	93.5	4.9	103.1	3.9
10	96.9	2.6	98.4	6.6	82.1	2.9	79.8	4.8	94.5	6.8	91.6	6.9	107.1	4.9
3	99.9	4.7	93.8	7.2	90.4	6.4	91.2	3.8	99.7	4.0	88.8	3.0	112.5	2.4
1	94.2	5.2	96.6	4.3	94.6	4.5	86.3	5.4	103.7	3.7	86.5	3.2	111.6	5.5
0.3	91.8	3.5	95.3	5.9	91.7	3.4	90.7	4.6	100.5	4.5	82.0	4.3	101.6	6.2
IC50	>30		>30		>30		>30		>30		>30		>30	

<b>2</b>	HL-60		Raji		K562		RPMI-8402		NALM6		U266		WSU-DLCL2	
( $\mu$ M)	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD
30	99.0	2.2	99.7	3.0	82.6	3.8	93.2	5.4	94.8	3.3	92.5	7.1	87.7	2.2
10	94.3	2.9	103.0	3.6	85.4	2.0	93.5	6.5	98.4	3.9	90.2	6.1	94.3	3.2
3	94.0	4.2	105.4	4.4	89.6	4.4	99.2	4.6	103.6	6.3	96.1	6.8	98.0	3.6
1	95.8	2.4	106.5	4.0	97.5	7.3	96.3	3.2	108.7	2.9	99.5	7.5	103.0	4.6
0.3	92.1	2.7	102.7	3.5	103.2	4.9	97.8	5.1	113.8	4.8	101.1	8.7	103.7	4.5
IC50	>30		>30		>30		>30		>30		>30		>30	

<b>3</b>	HL-60		Raji		K562		RPMI-8402		NALM6		U266		WSU-DLCL2	
( $\mu$ M)	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD
30	8.5	0.6	87.4	3.9	71.8	5.6	70.5	2.8	69.6	6.6	86.2	6.5	95.9	1.2
10	87.4	10.4	98.6	3.6	91.0	3.2	91.9	2.3	88.4	6.4	87.5	7.2	107.0	3.0
3	104.7	10.3	99.9	2.9	100.9	3.9	94.7	3.0	88.9	8.2	94.8	3.1	105.4	2.8
1	103.4	6.7	98.8	1.2	101.0	3.2	99.3	2.4	86.6	5.9	90.9	5.1	106.5	5.6
0.3	106.1	10.2	97.3	2.4	104.3	4.7	92.5	6.6	86.2	9.4	81.7	9.1	105.9	2.8
IC50	16.39	2.38	>30		>30		>30		>30		>30		>30	



<b>4</b>	HL-60		Raji		K562		RPMI-8402		NALM6		U266		WSU-DLCL2	
( $\mu$ M)	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD
30	94.9	2.4	82.6	8.4	36.0	1.1	38.1	1.1	9.7	1.8	99.1	2.7	69.1	5.7
10	94.9	2.9	120.3	7.8	109.7	5.0	97.6	2.7	92.1	7.1	104.9	1.6	105.6	0.9
3	91.3	4.3	105.7	4.4	109.5	6.2	96.3	2.2	84.8	8.3	102.9	6.6	104.4	2.8
1	94.3	1.0	102.7	5.7	112.8	6.1	91.6	1.5	92.2	3.5	105.1	3.1	93.2	2.8
0.3	92.0	4.0	98.0	5.5	113.9	3.8	92.4	2.6	85.2	5.5	108.5	6.5	84.5	2.9
IC50	>30		>30		28.23	0.85	26.39	0.63	17.75	1.73	>30		>30	

<b>5</b>	HL-60		Raji		K562		RPMI-8402		NALM6		U266		WSU-DLCL2	
( $\mu$ M)	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD
30	85.4	8.0	94.0	3.0	77.0	1.8	83.2	1.6	88.3	10.8	93.5	5.9	104.7	5.8
10	93.3	8.2	98.9	4.1	88.0	2.8	95.1	2.0	104.3	3.8	98.5	1.9	106.8	5.4
3	95.1	7.1	98.9	2.0	94.7	6.3	107.9	3.3	112.9	6.3	100.2	8.8	104.0	3.3
1	90.7	9.0	99.4	2.4	100.5	5.8	108.1	1.0	107.1	3.4	104.3	8.2	103.3	1.9
0.3	96.2	8.3	94.0	3.0	107.5	6.8	104.0	5.0	112.1	6.6	105.7	5.8	98.6	2.3
IC50	>30		>30		>30		>30		>30		>30		>30	

<b>6</b>	HL-60		Raji		K562		RPMI-8402		NALM6		U266		WSU-DLCL2	
( $\mu$ M)	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD
30	20.2	4.1	10.3	0.8	10.2	0.2	13.1	1.0	0.9	0.2	67.6	1.8	0.5	0.1
10	98.1	1.9	99.2	3.4	32.7	1.2	41.6	1.5	56.3	6.0	99.7	7.2	91.4	4.9
3	100.2	3.9	108.0	2.5	101.5	1.5	92.8	5.1	97.7	4.4	95.1	6.5	104.2	3.4
1	98.0	4.9	105.1	2.2	102.4	3.7	91.9	3.5	105.9	4.5	89.6	5.3	106.5	3.1
0.3	92.6	7.2	106.1	6.1	98.4	4.1	90.4	5.0	107.0	4.6	96.1	11.2	102.2	2.8
IC50	22.58	0.74	21.30	3.88	8.37	0.26	8.85	0.43	10.65	0.74	>30		14.03	1.17

7	HL-60		Raji		K562		RPMI-8402		NALM6		U266		WSU-DLCL2	
( $\mu$ M)	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD
30	98.7	3.9	120.4	3.0	98.6	5.0	100.2	2.3	88.9	4.3	99.5	4.2	107.9	2.6
10	98.3	4.6	111.9	2.2	106.8	7.9	97.5	2.4	96.7	4.8	101.8	5.2	108.9	2.5
3	90.8	2.2	111.7	4.0	98.3	8.5	96.9	4.0	87.1	7.5	103.2	2.5	105.7	2.8
1	96.1	3.5	109.3	7.9	100.8	9.8	90.9	5.1	97.6	4.0	103.1	2.9	94.6	6.9
0.3	91.6	2.3	101.1	8.0	102.8	6.0	88.0	4.9	99.9	5.8	101.5	6.9	87.1	6.9
IC50	>30		>30		>30		>30		>30		>30		>30	

8	HL-60		Raji		K562		RPMI-8402		NALM6		U266		WSU-DLCL2	
( $\mu$ M)	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD
30	83.6	4.5	52.8	2.0	17.7	3.9	27.4	1.6	8.7	0.4	90.6	3.0	36.8	8.4
10	93.1	3.8	98.3	3.9	85.1	0.7	99.5	5.9	109.3	7.5	103.9	9.3	100.5	6.2
3	93.4	3.6	98.1	3.7	100.5	5.0	107.4	6.3	93.7	3.2	101.4	4.5	97.5	4.6
1	92.5	3.0	95.7	4.8	99.2	6.6	105.4	6.5	93.9	10.6	100.7	6.4	98.9	2.7
0.3	93.7	1.1	94.3	4.4	102.0	3.5	106.2	4.6	96.8	7.7	97.1	7.4	100.1	1.2
IC50	>30		>30		17.94	1.05	25.37	2.90	24.77	1.22	>30		28.26	3.45

9	HL-60		Raji		K562		RPMI-8402		NALM6		U266		WSU-DLCL2	
( $\mu$ M)	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD
30	94.6	2.6	108.5	11.6	91.8	2.8	88.2	5.4	89.1	3.2	97.8	6.3	94.2	2.7
10	92.6	6.6	112.0	13.7	96.6	10.1	86.6	4.2	93.6	1.8	96.5	6.2	105.5	3.7
3	95.5	5.4	110.2	8.0	101.8	7.9	90.2	5.9	117.1	7.1	89.0	7.5	113.5	2.4
1	99.3	4.9	94.2	9.2	100.6	7.5	89.9	2.1	128.9	13.9	89.1	5.4	104.5	8.0
0.3	96.7	6.1	89.4	11.8	96.0	6.4	92.8	5.2	97.6	1.0	81.1	2.5	94.1	8.7
IC50	>30		>30		>30		>30		>30		>30		>30	

Doxorubicin HCl	HL-60		Raji		K-562		RPMI-8402		NALM6		U266		WSU-DLCL2	
( $\mu$ M)	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD
1	0.1	0.1	0.6	0.1	5.8	0.6	2.0	0.2	1.1	0.1	1.9	0.1	0.0	0.1
0.3	0.1	0.1	0.3	0.1	6.1	0.8	0.3	0.1	0.1	0.1	0.7	0.1	0.0	0.1
0.1	1.0	0.2	0.2	0.1	49.3	2.2	8.3	1.4	0.0	0.1	4.7	0.5	0.2	0.1
0.03	30.7	0.9	4.8	1.0	83.0	2.4	31.0	1.2	-0.1	0.0	60.3	3.2	3.1	0.3
0.01	69.3	1.5	46.6	5.5	97.8	2.7	69.3	2.4	0.4	0.1	96.3	4.3	14.5	1.4
0.003	90.8	1.7	75.6	3.8	100.3	3.7	85.6	5.1	57.6	4.7	81.2	3.4	56.7	1.7
0.001	96.9	1.4	102.9	2.2	102.3	4.5	101.9	6.5	100.0	5.4	93.1	3.6	95.0	4.9
0.0003	98.8	1.6	114.0	4.3	105.3	8.4	101.6	3.1	101.4	5.6	91.6	7.8	101.1	6.0
0.0001	102.3	5.2	116.1	2.9	115.3	3.7	103.0	6.6	100.0	5.8	95.3	5.2	102.1	3.0
IC50	0.0167	0.0010	0.0080	0.0010	0.0901	0.0020	0.0169	0.0000	0.0032	0.0000	0.0349	0.0010	0.0036	0.0000

**Figure S36.** Results of the cytotoxicity test of **1-9** against seven blood cancer cell lines.